- After nearly two and a half decades, Aurinia Pharmaceuticals' immunosuppressant voclosporin finally garnered FDA approval last week.
- After flunking a Phase 2/3 dry eye syndrome trial in October 2020, voclosporin for lupus nephritis (LN) is the only meaningful asset/indication for the company.
- With voclosporin likely to become the standard of care therapy for LN, a recently inked EU and Japanese collaboration, and insider buying, Aurinia merited a deeper dive.
- A full analysis and recommendation follows below.
For further details see:
Assessing Aurinia Pharmaceuticals Post FDA Approval